Lupus & antiphospholipid syndrome
Reduced organ damage accumulation in adult patients with systemic lupus erythematosus (SLE) on anifrolumab plus standard of care compared to real-world external controls
Main finding · Change in SDI score (weighted)Result — go to the resultMean change difference (lower) 0.416 points 95% CI −0.582 to −0.249Authors' conclusion
Patients who received anifrolumab accumulated significantly less organ damage after 208 weeks than patients who received RW SOC.
Study context
- Population
- Adults with moderately to severely active SLE
- Participants
- 354 vs 561
- Exposure
- Anifrolumab 300 mg plus standard of care (SOC) vs real-world SOC only
- Anifrolumabn = 354
- Real-world (RW) SOCn = 561reference
- Outcome
- Change in SLICC/ACR DI (SDI) score from baseline
- Follow-up
- Week 208
Methodological detailsreal-world external controls, propensity score and censoring weighting
- Real-world external controls
- Propensity score and censoring weighting
Main finding
Change in SDI score (weighted)
Mean change difference (lower)
0.416 points
95% CI −0.582 to −0.249
P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Time to first SDI score increase · within 208 weeks59.9% less likely | 0.401 (0.213–0.753) | P = 0.005 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls. Ann Rheum Dis. Published 1 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →